New Blood Pressure Drug Data Coming This November
Researchers will present findings on an experimental medication for hypertension that targets hormone regulation.
Updated on Sept. 23, 2026 in Heart Disease
Live Poll
Do you believe developing new targeted enzyme inhibitors is the right way to treat chronic hypertension?
Clinical trial data for lorundrostat, a new aldosterone synthase inhibitor, will be shared at the American Heart Association Scientific Sessions in Chicago from November 6 to November 9, 2026. This potential treatment is aimed at individuals with hypertension who have dysregulated aldosterone levels.
Why it matters
Sustained high blood pressure is a major risk factor for stroke and heart disease, contributing to over 685,000 deaths in the United States in 2022. Addressing hypertension through targeted biological pathways could offer new management options for patients who do not respond to traditional therapies.
The Transform-HTN trial, one of six late-stage studies conducted by the manufacturer, assesses the safety and efficacy of lorundrostat in patients with hypertension. While the drug has demonstrated a 40-70% reduction in plasma aldosterone, researchers are still investigating long-term clinical impacts.
The players
Mineralys Therapeutics
A pharmaceutical company headquartered in Radnor, Pennsylvania, focused on the development of lorundrostat.
Manish Saxena
A lead researcher scheduled to present findings on the Transform-HTN trial.
American Heart Association
A professional organization dedicated to cardiovascular health and the host of the upcoming scientific sessions.
The details
Lorundrostat functions as an aldosterone synthase inhibitor, targeting the CYP11B2 enzyme to lower aldosterone production. By reducing this hormone, which is dysregulated in approximately 30% of people with hypertension, the drug aims to lower elevated blood pressure. The medication features a 10-12 hour half-life, allowing for its specific pharmacokinetic profile within the body.
Timeline
The American Heart Association Scientific Sessions will be held November 6-9, 2026.
Data from the Transform-HTN trial will be presented on November 8, 2026.
Health Landscape
The presentation of the Transform-HTN trial data at the American Heart Association Scientific Sessions highlights the ongoing search for pharmacological alternatives to standard antihypertensive care. This research represents a move toward personalized medicine by identifying subsets of hypertensive patients who have specific hormonal dysregulation.
If you are managing hypertension, it is worth discussing with your doctor whether your current treatment plan addresses specific hormonal factors like aldosterone levels. Keep an eye on clinical trial announcements for new, evidence-based options that may become available for those who struggle to reach their blood pressure goals.
The takeaway
The development of aldosterone synthase inhibitors marks a potential shift in how we treat hypertension by targeting specific hormonal causes. Patients should monitor their blood pressure regularly and consult with their physician to understand how new clinical advancements may eventually apply to their care.
What happens next
The clinical trial results for lorundrostat will be formally presented on November 8, 2026, at the American Heart Association Scientific Sessions in Chicago.
Further reading
For more information on managing chronic conditions, visit the Heart Disease section.
More information
You can find more details in the Mineralys Therapeutics corporate information portal.
Live Poll
Do you believe developing new targeted enzyme inhibitors is the right way to treat chronic hypertension?
